ClearLight Biotechnologies
The Next Dimension in Tissue Analysis
Overview
2014
Healthcare & Pharmaceuticals
Biotech
B2B
Low
High
Balance Sheet
Cash and Cash Equivalents |
$718,333 |
Accounts and Notes Receivable |
$17,595 |
Property, Plant and Equipment (PP&E) |
$818,271 |
Total Assets |
$2,072,588 |
Accounts Payable & Accrued Liabilities |
$500,080 |
Total Liabilities |
$500,080 |
Total Stockholders' Equity |
$1,572,508 |
Total Liabilities and Equity |
$2,072,588 |
Statement of Comprehensive Income Information
Total Revenues |
$29,874 |
Costs & Expenses Applicable to Rev |
$157,760 |
Depreciation and Amortization |
$31,620 |
Net Income |
$-680,461 |
Earnings Per Share - Basic |
$-0.73 |
Earnings Per Share - Diluted |
$-0.73 |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual